Prenatal diagnosis innovation: Genome sequencing of maternal plasma

Annual Review of Medicine

Volumn 67, Issue , 2016, Pages 419-432

  Wong, Felix C K ^a,b   Lo, Y M Dennis ^a,b  

^a Li Ka Shing Institute of Health Sciences   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cell free DNA; Methylome; Next generation sequencing; Noninvasive prenatal testing; Transcriptome

Indexed keywords

DNA; NUCLEIC ACID; TRANSCRIPTOME;

ANEUPLOIDY; ARTICLE; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; DNA METHYLATION; FETUS MONITORING; FETUS RISK; GENE SEQUENCE; GENOME; HUMAN; MATERNAL PLASMA; MONOGENIC DISORDER; NEXT GENERATION SEQUENCING; NON INVASIVE PROCEDURE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; TRANSCRIPTOMICS; BLOOD; DNA MUTATIONAL ANALYSIS; FETAL DISEASES; GENETIC SCREENING; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM;

ANEUPLOIDY; DNA; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FETAL DISEASES; GENETIC TESTING; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRENATAL DIAGNOSIS; TRANSCRIPTOME;

EID: 84954515531     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-091014-115715     Document Type: Article

References (106)

1. Lo YM, Corbetta N, Chamberlain PF, et al. (1997). Presence of fetal DNA in maternal plasma and serum. Lancet 350: 485-87
2. Mujezinovic F, Alfirevic Z. (2007). Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet. Gynecol. 110: 687-94
3. Herzenberg LA, Bianchi DW, Schr öder J, et al. (1979). Fetal cells in the blood of pregnant women: detection and enrichment by fluorescence-Activated cell sorting. PNAS 76: 1453-55
4. Lo YM, Tein MS, Lau TK, et al. (1998). Quantitative analysis of fetalDNAinmaternal plasma and serum: implications for noninvasive prenatal diagnosis. Am. J. Hum. Genet. 62: 768-75
5. Lun FM, Chiu RW, Chan KC, et al. (2008). Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. Clin. Chem. 54: 1664-72
6. Lo YM, Zhang J, Leung TN, et al. (1999). Rapid clearance of fetal DNA from maternal plasma. Am. J. Hum. Genet. 64: 218-24
7. Masuzaki H, Miura K, Yoshiura KI, et al. (2004). Detection of cell free placentalDNAinmaternal plasma: direct evidence from three cases of confined placental mosaicism. J. Med. Genet. 41: 289-92
8. Alberry M, Maddocks D, Jones M, et al. (2007). Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast. Prenat. Diagn. 27: 415-18
9. Rijnders RJ, Van Der Luijt RB, Peters ED, et al. (2003). Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenat. Diagn. 23: 1042-44
10. Lui YY, Chik KW, Chiu RW, et al. (2002). Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin. Chem. 48: 421-27
11. Lun FM, Chiu RW, Sun K, et al. (2013). Noninvasive prenatal methylomic analysis by genomewide bisulfite sequencing of maternal plasma DNA. Clin. Chem. 59: 1583-94
12. Chan KC, Zhang J, Hui AB, et al. (2004). Size distributions of maternal and fetalDNAinmaternal plasma. Clin. Chem. 50: 88-92
13. Lo YM, Chan KC, Sun H, et al. (2010). Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci. Transl. Med. 2: 61ra91
14. Lo YM. (2013). Non-invasive prenatal testing using massively parallel sequencing of maternal plasma DNA: from molecular karyotyping to fetal whole-genome sequencing. Reprod. Biomed. Online 27: 593-98
15. Chiu RW, Lo YM. (2013). Clinical applications of maternal plasma fetal DNA analysis: translating the fruits of 15 years of research. Clin. Chem. Lab. Med. 51: 197-204
16. Sims D, Sudbery I, Ilott NE, et al. (2014). Sequencing depth and coverage: key considerations in genomic analyses. Nat. Rev. Genet. 15: 121-32
17. Driscoll DA, Gross SJ. (2009). Screening for fetal aneuploidy and neural tube defects. Professional Practice Guidelines Committee. Genet. Med. 11: 818-21
18. Chiu RW, Chan KC, Gao Y, et al. (2008). Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. PNAS 105: 20458-63
19. Fan HC, Blumenfeld YJ, Chitkara U, et al. (2008). Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. PNAS 105: 16266-71
20. Liao GJ, Lun FM, Zheng YW, et al. (2011). Targeted massively parallel sequencing of maternal plasma DNA permits efficient and unbiased detection of fetal alleles. Clin. Chem. 57: 92-101
21. Liao GJ, Chan KC, Jiang P, et al. (2012). Noninvasive prenatal diagnosis of fetal trisomy 21 by allelic ratio analysis using targeted massively parallel sequencing of maternal plasma DNA. PLoS ONE 7: e38154
22. Zimmermann B, Hill M, Gemelos G, et al. (2012). Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat. Diagn. 32: 1233-41
23. Sparks AB, Struble CA, Wang ET, et al. (2012). Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am. J. Obstet. Gynecol. 206: 319.e1-9
24. Sparks AB, Wang ET, Struble CA, et al. (2012). Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat. Diagn. 32: 3-9
25. Juneau K, Bogard PE, Huang S, et al. (2014). Microarray-based cell-free DNA analysis improves noninvasive prenatal testing. Fetal Diagn. Ther. 36: 282-86
26. Chiu RW, Akolekar R, Zheng YW, et al. (2011). Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 342: c7401
27. Sehnert AJ, Rhees B, Comstock D, et al. (2011). Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin. Chem. 57: 1042-49
28. Palomaki GE, Deciu C, Kloza EM, et al. (2012). DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet. Med. 14: 296-305
29. Ehrich M, Deciu C, Zwiefelhofer T, et al. (2011). Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am. J. Obstet. Gynecol. 204: 205.e1-11
30. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. (2011). DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet. Med. 13: 913-20
31. Bianchi DW, Platt LD, Goldberg JD, et al. (2012). Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet. Gynecol. 119: 890-901
32. Norton ME, Brar H, Weiss J, et al. (2012). Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am. J. Obstet. Gynecol. 207: 137.e1-8
33. Nicolaides KH, Syngelaki A, Gil M, et al. (2013). Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat. Diagn. 33: 575-79
34. Gil MM, Akolekar R, Quezada MS, et al. (2014). Analysis of cell-free DNA inmaternal blood in screening for aneuploidies: meta-Analysis. Fetal Diagn. Ther. 35: 156-73
35. Gil MM, Quezada MS, Revello R, et al. (2015). Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-Analysis. Ultrasound Obstet. Gynecol. 45: 249-66
36. Wegrzyn P, Faro C, Falcon O, et al. (2005). Placental volume measured by three-dimensional ultrasound at 11 to 13 + 6 weeks of gestation: relation to chromosomal defects. Ultrasound Obstet. Gynecol. 26: 28-32
37. Benn P, Borrell A, Crossley J, et al. (2011). Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011. Prenat. Diagn. 31: 519-22
38. American College of Obstetricians and Gynecologists Committee on Genetics. (2012). Committee Opinion No. 545: noninvasive prenatal testing for fetal aneuploidy. Obstet. Gynecol. 120: 1532-4
39. Devers PL, Cronister A, Ormond KE, et al. (2013). Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J. Genet. Couns. 22: 291-95
40. Gregg AR, Gross SJ, Best RG, et al. (2013). ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet. Med. 15: 395-98
41. Langlois S, Brock JA, Wilson RD, et al. (2013). Current status in non-invasive prenatal detection ofDown syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma. J. Obstet. Gynaecol. Can. 35: 177-83
42. Hudecova I, Sahota D, Heung MM, et al. (2014). Maternal plasma fetal DNA fractions in pregnancies with low and high risks for fetal chromosomal aneuploidies. PLoS ONE 9: e88484
43. Nicolaides KH, Syngelaki A, Ashoor G, et al. (2012). Noninvasive prenatal testing for fetal trisomies in a routinely screened first-Trimester population. Am. J. Obstet. Gynecol. 207: 374.e1-6
44. Dan S, Wang W, Ren J, et al. (2012). Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11, 105 pregnancies with mixed risk factors. Prenat. Diagn. 32: 1225-32
45. Bianchi DW, Parker RL, Wentworth J, et al. 2014.DNAsequencing versus standard prenatal aneuploidy screening. N. Engl. J. Med. 370: 799-808
46. Norton ME, Jacobsson B, Swamy GK, et al. (2015). Cell-free DNA analysis for noninvasive examination of trisomy. N. Engl. J. Med. 372: 1589-97
47. Searle CJ, Smith K, Daniels G, et al. (2013). Cell-free fetal DNA sex determination identified a maternal SRY gene with a known X chromosome deletion. Prenat. Diagn. 33: 612-13
48. Lau TK, Jiang FM, Stevenson RJ, et al. (2013). Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service. Prenat. Diagn. 33: 602-8
49. Snyder MW, Simmons LE, Kitzman JO, et al. (2015). Copy-number variation and false positive prenatal aneuploidy screening results. N. Engl. J. Med. 372: 1639-45
50. Wang Y, Chen Y, Tian F, et al. (2014). Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin. Chem. 60: 251-59
51. Pan M, Li FT, Li Y, et al. (2013). Discordant results between fetal karyotyping and non-invasive prenatal testing by maternal plasma sequencing in a case of uniparental disomy 21 due to trisomic rescue. Prenat. Diagn. 33: 598-601
52. Canick JA, Kloza EM, Lambert-Messerlian GM, et al. (2012). DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. Prenat. Diagn. 32: 730-34
53. Leung TY, Qu JZ, Liao GJ, et al. (2013). Noninvasive twin zygosity assessment and aneuploidy detection by maternal plasma DNA sequencing. Prenat. Diagn. 33: 675-81
54. Qu JZ, Leung TY, Jiang P, et al. (2013). Noninvasive prenatal determination of twin zygosity by maternal plasma DNA analysis. Clin. Chem. 59: 427-35
55. Peters D, Chu T, Yatsenko SA, et al. (2011). Noninvasive prenatal diagnosis of a fetal microdeletion syndrome. N. Engl. J. Med. 365: 1847-48
56. Jensen TJ, Dzakula Z, Deciu C, et al. (2012). Detection of microdeletion 22q11.2 in a fetus by nextgeneration sequencing of maternal plasma. Clin. Chem. 58: 1148-51
57. Yu SC, Jiang P, Choy KW, et al. (2013). Noninvasive prenatal molecular karyotyping from maternal plasma. PLoS ONE 8: e60968
58. Srinivasan A, Bianchi DW, Huang H, et al. (2013). Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma. Am. J. Hum. Genet. 92: 167-76
59. Chen S, Lau TK, Zhang C, et al. (2013). A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing. Prenat. Diagn. 33: 584-90
60. Straver R, Sistermans EA, Holstege H, et al. (2014). WISECONDOR: detection of fetal aberrations from shallow sequencing maternal plasma based on a within-sample comparison scheme. Nucleic Acids Res. 42: e31
61. Zhao C, Tynan J, Ehrich M, et al. (2015). Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clin. Chem. 61: 608-16
62. Wapner RJ, Babiarz JE, Levy B, et al. (2015). Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am. J. Obstet. Gynecol. 212: 332.e1-9
63. Slavotinek A. (2012). Microdeletion syndromes. eLS: Citable Reviews in the Life Sciences. Chichester, UK: Wiley. http://www.els.net. doi: 10.1002/9780470015902.a0005549.pub2
64. Lo YM, Hjelm NM, Fidler C, et al. (1998). Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N. Engl. J. Med. 339: 1734-38
65. González-González MC, Trujillo MJ, Rodríguez de Alba M, et al. (2003). Huntington disease-unaffected fetus diagnosed from maternal plasma using QF-PCR. Prenat. Diagn. 23: 232-34
66. Amicucci P, Gennarelli M, Novelli G, Dallapiccola B. (2000). Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin. Chem. 46: 301-2
67. Meaney C, Norbury G. (2009). Noninvasive prenatal diagnosis of early onset primary dystonia I inmaternal plasma. Prenat. Diagn. 29: 1218-21
68. Chitty LS, Griffin DR, Meaney C, et al. (2011). New aids for the non-invasive prenatal diagnosis of achondroplasia: dysmorphic features, charts of fetal size and molecular confirmation using cell-free fetal DNA in maternal plasma. Ultrasound Obstet. Gynecol. 37: 283-89
69. Chitty LS, Khalil A, Barrett AN, et al. (2013). Safe, accurate, prenatal diagnosis of thanatophoric dysplasia using ultrasound and free fetal DNA. Prenat. Diagn. 33: 416-23
70. Chitty LS, Mason S, Barrett AN, et al. (2015). Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach. Prenat. Diagn. 35: 656-62
71. Lun FM, Tsui NB, Chan KC, et al. (2008). Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. PNAS 105: 19920-25
72. Barrett AN, McDonnell TC, Chan KC, Chitty LS. (2012). Digital PCR analysis of maternal plasma for noninvasive detection of sickle cell anemia. Clin. Chem. 58: 1026-32
73. Tsui NB, Kadir RA, Chan KC, et al. (2011). Noninvasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA. Blood 117: 3684-91
74. Lam KW, Jiang P, Liao GJ, et al. (2012). Noninvasive prenatal diagnosis ofmonogenic diseases by targeted massively parallel sequencing of maternal plasma: application to β-Thalassemia. Clin. Chem. 58: 1467-75
75. New MI, Tong YK, Yuen T, et al. (2014). Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. J. Clin. Endocrinol. Metab. 99: E1022-30
76. Fan HC, Gu W, Wang J, et al. (2012). Non-invasive prenatal measurement of the fetal genome. Nature 487: 320-24
77. Kitzman JO, Snyder MW, Ventura M, et al. (2012). Noninvasive whole-genome sequencing of a human fetus. Sci. Transl. Med. 4: 137ra76
78. Chen S, Ge H, Wang X, et al. (2013). Haplotype-Assisted accurate non-invasive fetal whole genome recovery through maternal plasma sequencing. Genome Med. 5: 18
79. Fan HC, Wang J, Potanina A, Quake SR. (2011). Whole-genome molecular haplotyping of single cells. Nat. Biotechnol. 29: 51-57
80. Kitzman JO, Mackenzie AP, Adey A, et al. (2011). Haplotype-resolved genome sequencing of a Gujarati Indian individual. Nat. Biotechnol. 29: 59-63
81. Peters BA, Kermani BG, Sparks AB, et al. (2012). Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. Nature 487: 190-95
82. Snyder MW, Simmons LE, Kitzman JO, et al. (2013). Noninvasive fetal genome sequencing: a primer. Prenat. Diagn. 33: 547-54
83. Suzuki MM, Bird A. (2008). DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9: 465-76
84. Eckhardt F, Lewin J, Cortese R, et al. (2006). DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet. 38: 1378-85
85. Weber M, Hellmann I, Stadler MB, et al. (2007). Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 39: 457-66
86. Illingworth R, Kerr A, Desousa D, et al. 2008.AnovelCpGisland set identifies tissue-specificmethylation at developmental gene loci. PLoS Biol. 6: e22
87. Rakyan VK, Down TA, Thorne NP, et al. (2008). An integrated resource for genome-wide identification and analysis of human tissue-specific differentially methylated regions (tDMRs). Genome Res. 18: 1518-29
88. Chim SS, Tong YK, Chiu RW, et al. (2005). Detection of the placental epigenetic signature of the maspin gene in maternal plasma. PNAS 102: 14753-58
89. Chan KC, Ding C, Gerovassili A, et al. (2006). Hypermethylated RASSF1A in maternal plasma: a universal fetalDNAmarker that improves the reliability of noninvasive prenatal diagnosis. Clin. Chem. 52: 2211-18
90. Tong YK, Ding C, Chiu RW, et al. (2006). Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: theoretical and empirical considerations. Clin. Chem. 52: 2194-202
91. Tong YK, Chiu RW, Akolekar R, et al. (2010). Epigenetic-genetic chromosome dosage approach for fetal trisomy 21 detection using an autosomal genetic reference marker. PLoS ONE 5: e15244
92. Tong YK, Jin S, Chiu RW, et al. (2010). Noninvasive prenatal detection of trisomy 21 by an epigeneticgenetic chromosome-dosage approach. Clin. Chem. 56: 90-98
93. Tsui DW, Lam YM, Lee WS, et al. (2010). Systematic identification of placental epigenetic signatures for the noninvasive prenatal detection of Edwards syndrome. PLoS ONE 5: e15069
94. Papageorgiou EA, Karagrigoriou A, Tsaliki E, et al. (2011). Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat. Med. 17: 510-13
95. Yuen RK, Peñaherrera MS, von Dadelszen P, et al. 2010.DNAmethylation profiling of human placentas reveals promoter hypomethylation of multiple genes in early-onset preeclampsia. Eur. J. Hum. Genet. 18: 1006-12
96. Blair JD, Yuen RK, Lim BK, et al. (2013). Widespread DNA hypomethylation at gene enhancer regions in placentas associated with early-onset pre-eclampsia. Mol. Hum. Reprod. 19: 697-708
97. Chu T, Bunce K, Shaw P, et al. (2014). Comprehensive analysis of preeclampsia-Associated DNA methylation in the placenta. PLoS ONE 9: e107318
98. Poon LL, Leung TN, Lau TK, Lo YM. (2000). Presence of fetal RNA in maternal plasma. Clin. Chem. 46: 1832-34
99. Pang WW, Tsui MH, Sahota D, et al. (2009). A strategy for identifying circulating placental RNAmarkers for fetal growth assessment. Prenat. Diagn. 29: 495-504
100. Ng EK, Leung TN, Tsui NB, et al. (2003). The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. Clin. Chem. 49: 727-31
101. Lo YM, Tsui NB, Chiu RW, et al. (2007). Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat. Med. 13: 218-23
102. Tsui NB, Wong BC, Leung TY, et al. (2009). Non-invasive prenatal detection of fetal trisomy 18 by RNA-SNP allelic ratio analysis using maternal plasma SERPINB2 mRNA: a feasibility study. Prenat. Diagn. 29: 1031-37
103. Tsui NB, Jiang P, Wong YF, et al. (2014). Maternal plasma RNA sequencing for genome-wide transcriptomic profiling and identification of pregnancy-Associated transcripts. Clin. Chem. 60: 954-62
104. Koh W, Pan W, Gawad C, et al. (2014). Noninvasive in vivo monitoring of tissue-specific global gene expression in humans. PNAS 111: 7361-66
105. Hahn S, Rusterholz C, Hösli I, Lapaire O. (2011). Cell-free nucleic acids as potential markers for preeclampsia. Placenta 32(Suppl.): S17-20
106. Oudejans CBM. (2015). Maternal plasma RNA sequencing. Clin. Biochem. 48: 942-47